Table 1.
Baseline Characteristics of the study group
| Overall | Baseline CD4 stratum |
p | ||
|---|---|---|---|---|
| (N=300) | 201–350 (N=114) |
>350 (N=186) |
||
| Age (median, IQR) | 31 (27 – 37) | 32 (27 – 38) | 31 (26 – 36) | 0.25 |
|
| ||||
| Gender (Female) (%) | 245 (82) | 90 (79) | 155 (83) | 0.34 |
|
| ||||
| pVL >100,000 copies/ml (%) | 107 (36) | 57 (50) | 50 (27) | <0.0001 |
|
| ||||
| CTL responders (%) | ||||
| p24Gag | 232 (77) | 82 (72) | 150 (81) | 0.08 |
| Pol | 244 (81) | 98 (86) | 146 (78) | 0.11 |
| Env | 127 (42) | 52 (46) | 75 (40) | 0.37 |
| Acc/Reg | 263 (88) | 97 (85) | 166 (89) | 0.29 |
|
| ||||
| Protective HLA allele (%) | 116 (39) | 49 (43) | 67 (36) | 0.23 |
|
| ||||
| CD4 measurements/subject | 8 (4 – 11) | 7 (3 – 9) | 9 (6 – 12) | <0.0001 |
|
| ||||
| Median Follow-up months (IQR) | 25 (15 – 41) |
21 (10 – 28) |
27 (20 – 45) |
<0.0001 |
IQR=Interquartile range